Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

66.67 +0.14 (+0.20%)
Streaming Delayed Price Updated: 12:09 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
26 27 Next >
14 Stocks in the Healthcare Sector
Here are 14 companies in the Healthcare Sector that have investment-grade credit ratings of BBB- or better, cash flow yield of 6% or better, future total return of at least 5%. 
Via Talk Markets
3 Blue Chip Stocks Growing Their Earnings And Dividends
In times of elevated stock market volatility, investors should consider quality blue chip stocks like BMY, LYB, and VZ. 
Via Talk Markets
3 Healthcare Stocks Ignoring the Market Mayhem
Sellers dominate the Street this week, but some healthcare stocks remain unaffected. Here are three to put atop your watchlist. 
Via InvestorPlace
3 Pharma Stocks Yielding Over 3%
The Pharma industry faced headwinds in 2021 as hospitals delayed procedures and elective surgeries. 
Via Talk Markets
More Serious Matters
Wall Street fell on new worries about inflation and a drop in retail sales levels. 
Via Talk Markets
Weakness Is Turning Into Opportunity For Bristol Myers Squibb
With plenty of strong catalysts, shares of BMY are just beginning to pivot higher. 
Via Talk Markets
Looking Into Bristol-myers Squibb Company's Recent Short Interest
Bristol-myers Squibb Company's (NYSE:BMY) short percent of float has fallen 5.71% since last its last report. The company recently reported that it has 21.93 million shares sold... 
Via Benzinga
This Company Believes Physics, Not Chemistry, Is the Best Way To Develop Successful Protein Therapeutics
Picture credit: Michael Longmire on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing... 
Via Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
Interest Rate Hikes And Stocks
Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore. 
Via Talk Markets
Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum
2seventy bio Inc's (NASDAQ: TSVT) anti-BCMA CAR-T got axed as part of a corporate update. The treatment was under development in collaboration with Bristol... 
Via Benzinga
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo... 
Via Benzinga
Start Of The Week
British property (real estate) stocks fell today. 
Via Talk Markets
3 Top Stock Trades for the Week of Jan. 10, 2022
Sellers continue to push their advantage making it necessary to play defense to win. Here are three top stock trades for the new week. 
Via InvestorPlace
Bristol Myers Squibb Shares Jump After J.P. Morgan Healthcare Conference Presentation
Bristol Myers Squibb Co (NYSE: BMY) kicked off the Big Pharma presentations at the J.P. Morgan healthcare conference. The execs said the drugmaker aims to grow despite... 
Via Benzinga
Why Bristol-Myers Squibb Shares Are Trading Higher Today
Bristol-Myers Squibb Co (NYSE: BMY) is trading higher Monday after the company announced a $5 billion buyback and issued FY22 financial guidance. Bristol-Myers said it... 
Via Benzinga
Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies
Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to... 
Via Benzinga
Bristol-Myers Squibb's Debt Overview
Shares of Bristol-Myers Squibb (NYSE:BMY) increased by 8.89% in the past three months. Before having a look at the importance of debt, let us look at how much debt Bristol-... 
Via Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
53 Firms Going Ex-Dividend Next Week, Including Comcast, AT&T And General Mills
There are several well known large cap stocks going ex-dividend next week including nine of our Top 100 Dividend Stocks. 
Via Talk Markets
Best Stocks for 2022: Bristol-Myers Squibb Will Offer Huge Returns
Bristol-Myers Squibb offers a substantial dividend, but that's far from the only reason that BMY stock is a great investment for 2022. 
Via InvestorPlace
7 Dividend Increases Expected In January 2022
How many dividend increases are you going to receive this month? How many stocks on this list do you own? Are you ready to crush it in 2022? 
Via Talk Markets
Market Trend: Erratic And Unreliable
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is. 
Via Talk Markets
Peering Into Bristol-myers Squibb Company's Recent Short Interest
Bristol-myers Squibb Company's (NYSE:BMY) short percent of float has risen 14.13% since last its last report. The company recently reported that it has 23.26 million shares sold... 
Via Benzinga
Best Stocks For Wheel Strategy Trades: Use These In 2022
Blue chips companies, high dividend stocks, REITs, and low beta ETFs work well when employing the wheel strategy. 
Via Talk Markets
Biotech Playbook 2021 Part 2: Rotation Rally Brings Relief after FED Pivot
The new aggressive Fed taper combined with a rise in interest rates for 2022 adds a new element of risk to portfolio management. Monetary policy is a headwind for 2022. 
Via Talk Markets
Buy Time: Dirt Cheap, Pays A Market-Beating Yield, And Just Announced A $15 Billion Share Buyback
The US stock market’s resilience is amazing. It started off November with a hard dip in response to the Omicron variant news. 
Via Talk Markets
Dreaming Of A Red Christmas
The stock market is reacting with lots of selling to the weekend's news. 
Via Talk Markets
The Week Ahead In Biotech (Dec. 19-25): Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some... 
Via Talk Markets
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also... 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.